Market Place
Sourcing Support
Sarepta Provides Regulatory Update on Amondys 45 and Vyondys 53
19 Mar 2026 //
BUSSINESSWIRE
Sarepta Announces Call for Applications for 9th Annual Route 79
27 Feb 2026 //
BUSINESSWIRE
Sarepta CEO to Retire, Citing Health and Ironic Twist
26 Feb 2026 //
FIERCE PHARMA
Sarepta Pharma Reveals 2025 Q4 Financial And Corporate Updates
25 Feb 2026 //
BUSINESSWIRE
Sarepta Therapeutics To Report 2025 Q4 And Full-Year Financials
11 Feb 2026 //
BUSINESSWIRE
Sarepta Reports 2025 Net Product Revenues For Q4 And Full Year
12 Jan 2026 //
BUSINESSWIRE
Sarepta Awards Inducements Under Nasdaq Rule 5635(c)(4)
31 Dec 2025 //
BUSINESSWIRE
Sarepta Refinances $291M 1.25% Convertible Notes
11 Dec 2025 //
BUSINESSWIRE
Sarepta Therapeutics To Report Q3 2025 Financial Results
27 Oct 2025 //
BUSINESSWIRE
Sarepta Issues Inducement Grants Per Nasdaq LR 5635(c)(4)
30 Sep 2025 //
BUSINESSWIRE
Sarepta Therapeutics Reveal Route 79 Duchenne Scholarship Program
05 Sep 2025 //
BUSINESSWIRE
Arena BioWorks Lays Off Staff 19 Months After Launch
22 Aug 2025 //
FIERCE BIOTECH
Sarepta`s Issues Cast AAV Under Harsh Scrutiny
11 Aug 2025 //
BIOSPACE
Sarepta Therapeutics Reveals Q2 2025 Financial Results & Updates
06 Aug 2025 //
BUSINESSWIRE
Sarepta Therapeutics Set to Reveal Q2 2025 Financial Results
31 Jul 2025 //
BUSINESSWIRE
FDA Probes 3rd Elevidys Patient Death
28 Jul 2025 //
FIERCE PHARMA
Sarepta Stands Ground Against HHS Request To Stop Shipment
21 Jul 2025 //
BIOSPACE
Sarepta Announces Grants Under Nasdaq Rule 5635(c)(4)
30 Jun 2025 //
BUSINESSWIRE
Sarepta Stock Falls After Second Death Linked to Gene Therapy
16 Jun 2025 //
REUTERS
Sarepta Therapeutics to Present at BofA Securities Conference
08 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q1 2025 Financials and Updates
06 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Announce Q1 2025 Financial Results
22 Apr 2025 //
BUSINESSWIRE
Sarepta Opens Applications For 8th Route 79 Duchenne Scholarship
28 Feb 2025 //
BUSINESSWIRE
Sarepta To Announce Q4 & Full-Year 2024 Results
12 Feb 2025 //
BUSINESSWIRE
Arrowhead & Sarepta Close Global License Agreement
10 Feb 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
10 Feb 2025 //
BUSINESSWIRE
Sarepta Therapeutics to Present at 43rd J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Sarepta Wins 115.2 M US Drug Patent Verdict from Nippon Shinyaku
23 Dec 2024 //
REUTERS
FDA`s Accelerated Approval Drives Momentum for Fatal Diseases
02 Dec 2024 //
BIOSPACE
Sarepta`s Elevidys blows sales expectations out of the water
07 Nov 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Under Nasdaq Rule
30 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rules
30 Aug 2024 //
BUSINESSWIRE
Sarepta Therapeutics Reports Q2 2024 Results And Corporate Developments
07 Aug 2024 //
BUSINESSWIRE
Sarepta Faces Lower Revenue For Duchenne Gene Therapy
07 Aug 2024 //
ENDPTS
Sarepta Therapeutics Announces Inducement Grants
31 Jul 2024 //
BUSINESSWIRE
Sanofi sues Sarepta, claiming Duchenne gene therapy Elevidys infringes 2 manufacturing patents
31 Jul 2024 //
FIERCE PHARMA
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
29 Jul 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
28 Jun 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
28 Jun 2024 //
BUSINESSWIRE
Great Point Partners acquires German CDMO Lyocontract
13 Jun 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Per Nasdaq Rule
31 May 2024 //
BUSINESSWIRE
Sarepta Therapeutics executive sells $508,900 in stock
07 May 2024 //
INVESTING
Sarepta Q1 2024 Results, Recent Corporate Developments
01 May 2024 //
BUSINESSWIRE
Sarepta Therapeutics Inducement Grants Under Nasdaq 5635(c)(4)
30 Apr 2024 //
BUSINESSWIRE
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
24 Apr 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Mar 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
19 Mar 2024 //
PRESS RELEASE
US spent $3B on DMD treatments
12 Mar 2024 //
ENDPTS
Sarepta Therapeutics to Present at Upcoming Investor Conferences
04 Mar 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Feb 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79
29 Feb 2024 //
PRESS RELEASE
Sarepta Announces Fourth Quarter and Full-Year 2023 Financial Results
28 Feb 2024 //
BUSINESSWIRE
Sarepta to Announce Fourth Quarter and Full-Year 2023 Financial Results
21 Feb 2024 //
BUSINESSWIRE
Sarepta`s Elevidys expansion bid gets fast review without adcomm
16 Feb 2024 //
FIERCE PHARMA
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2024 //
BUSINESSWIRE
Sarepta Therapeutics Initiates Screening in Phase 3 Study of SRP-9003
16 Jan 2024 //
PRESS RELEASE
Sarepta Reports Preliminary* Fourth Quarter & Full-Year 2023 Net Product Revenue
08 Jan 2024 //
BUSINESSWIRE
Sarepta to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Dec 2023 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Nov 2023 //
PRESS RELEASE
